This site is intended for health professionals only

Published on 4 May 2007

Share this story:
Twitter
LinkedIn

MHRA issues safety information on medicines for healthcare professionals

teaser

The MHRA has compiled a list of letters sent to UK healthcareprofessionals in April 2007, to deliver new safety information andadvice. Topics include:

• Mabthera® (rituximab): reports ofprogressive multifocal leukoencephalopathy in unapproved indications ofsystemic lupus erythematosus and vasculitis.

• Pioglitazone-containing products: risk of fractures in women on long-term treatment.

• Cabaser® (cabergoline): pathological gambling and increased libido are potential class effects of dopamine agonists.

• Desmopressin: removal of primary nocturnal enuresis indication.

• Ketek® (telithromycin): important information about restricted indications, contraindications and safety measures.

•Ventolin® (salbutamol): new prescribing advice for obstetric use inmanagement of preterm labour and use in respiratory disease.

New Electronic Library for Medicines 2/5/2007

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn